Evidence map›Paper›PMID 38675476›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

FRET Assays for the Identification of

Philip Kohlmann, Sergey N Krylov, Pascal Marchand, Joachim Jose

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Philip KohlmannInstitute of Pharmaceutical and Medicinal Chemistry, Pharmacampus, University of Münster, 48149 Münster, Germany.
Sergey N KrylovDepartment of Chemistry, York University, Toronto, ON M3J 1P3, Canada.
Pascal MarchandCibles et Médicaments des Infections et de l'Immunité, IICiMed, Nantes Université, UR 1155, F-44000 Nantes, France.ORCID 0000-0001-7773-8642
Joachim JoseInstitute of Pharmaceutical and Medicinal Chemistry, Pharmacampus, University of Münster, 48149 Münster, Germany.ORCID 0000-0002-0666-2676
University of Münster · DECibles et Médicaments des Infections et de l'ImmunitéYork University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heat shock protein 90 (HSP90) is a critical target for anticancer and anti-fungal-infection therapies due to its central role as a molecular chaperone involved in protein folding and activation. In this study, we developed

Indexed as

accuracy assessment of Kdcancerdrug discoveryFRETfungal infectionshigh-throughput screening (HTS) capabilityHSP90p23Sba1

Identifiers

PMID38675476
PMCPMC11053944
OpenAlexW4394878935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.